Latest News - Danaher
Top Corporates Hub
Danaher
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
14.08.2026 00:13
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]
Major Acquisition Alert: Julie A. Sawyer Montgomery Acquires $1.93M In Danaher Stock Options
07.08.2026 11:02
A noteworthy insider acquisition was disclosed on August 6, as Montgomery, Executive Vice President at Danaher (NYSE:DHR), reported the acquisition of stock options for 245,701 shares. What Happened: A Form 4 filing
Witness A Substantial Acquisition As Christopher Bouda Acquires $96K In Danaher Stock Options
07.08.2026 11:02
In a new SEC filing on August 6, it was unveiled that Bouda, VP at Danaher (NYSE:DHR), acquired stock options for 12,286 shares. What Happened: Bouda, VP at Danaher, engaged in a derivative transaction according to a
Matthew E Gugino Makes Strategic Play: Invests $654K In Danaher Stock Options
07.08.2026 11:02
A substantial acquisition of company stock options by Matthew E Gugino, EVP & Chief Financial Officer at Danaher (NYSE:DHR) was reported on August 6, based on a new SEC filing. What Happened: Gugino, EVP & Chief
[Latest] Global AI In Digital Pathology Market Size/Share Worth USD 5.14 Billion by 2035 at a 18.02% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
05.08.2026 10:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global AI In Digital Pathology Market size & share revenue was valued at approximately USD 0.98 Billion in 2025 and is expected to reach USD 1.15 Billion in 2026 and is expected to reach around USD 5.14 Billion by 2035, at a CAGR of 18.02% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Leica Biosystems (Danahe
Can Danaher (DHR) Trade At A Discount After Its CEO Change?
05.08.2026 00:20
Danaher stock now sits around US$194.78 after a weak earnings update and a leadership change on the horizon, and investors are weighing a Discounted Cash Flow (DCF) intrinsic value estimate that points to upside against market multiples that still flag the shares as expensive. Over the past 5 years, Danaher shares have declined about 27.1%, which means long term holders are still under water even before considering valuation. The sharp selloff after the recent earnings miss and the planned...
Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
31.07.2026 19:31
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
24.07.2026 12:54
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
The 'Standout Performance' That Could Save Thermo Fisher, Danaher And Others
23.07.2026 13:42
Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.
Danaher (DHR) Q2 2026 Earnings Call Transcript
22.07.2026 00:30
Non-respiratory growth accelerated 150 basis points as life sciences recovered.
Stocks Rise Pre-Bell as Investors Await More Earnings, Monitor Middle East Developments
21.07.2026 11:48
US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora
Danaher shares slide despite second-quarter earnings and revenue beat (DHR)
21.07.2026 11:16
Strong quarterly performance overshadowed by softer near-term outlookDanaher Corporation (NYSE:DHR) reported second-quarter results that exceeded Wall Street expectations, but investors focused on a more cautious growth outlook for the current quarter, sending the shares down 9% in pre-market trading. The life sciences and diagnostics company posted adjusted earnings per share of $1.
Tech Rebound Boosts Wall Street Pre-Bell; Asia, Europe Up
21.07.2026 11:10
Wall Street futures pointed higher pre-bell Tuesday as tech traders toggled risk-on switches despite
Danaher shares tumble despite earnings beat
21.07.2026 10:49
Investing.com -- Danaher Corporation (NYSE:DHR) reported second quarter results that exceeded analyst expectations, but shares fell 9% premarket.
Danaher (NYSE:DHR) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops
21.07.2026 10:23
Diversified science and technology company Danaher (NYSE:DHR) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.5% year on year to $6.27 billion. Its non-GAAP profit of $1.94 per share was 4.9% above analysts’ consensus estimates.
Danaher Reports Second Quarter 2026 Results
21.07.2026 10:00
Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Danaher Corporation 2026 Q2 - Results - Earnings Call Presentation
21.07.2026 08:30
2026-07-21. The following slide deck was published by Danaher Corporation in conjunction with their 2026 Q2 earnings call.
Danaher (DHR) Q2 Earnings Report Preview: What To Look For
20.07.2026 05:09
Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market hours. Here’s what you need to know.
Danaher (DHR) Stock May Trade At A Discount Despite Its 18% Five Year Decline
17.07.2026 05:09
Danaher stock presents a clear valuation tension right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the earnings based multiples suggest the shares are already pricing in a premium. Over the past 5 years, Danaher shareholders have seen the stock decline about 18%, which frames the current valuation debate against a weaker long term return profile. Recent news around portfolio moves in diagnostics and pathology can support expectations...
Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?
17.07.2026 02:14
Danaher, which released its Q2 2026 results on 21 July, saw expectations firm up ahead of the report as analysts projected modest year-on-year growth in revenue and earnings, helped by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition despite cost pressures and higher debt. Investors are focusing on how Masimo’s integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics and rising input,...